TEVA/MYL—“Regulatory blockage” as in objections from antitrust regulators. There are only five large global generic-drug companies remaining, so combining two of them is likely to be viewed as anticompetitive by at least one regulatory body who has veto power over the deal.
Roy has my meaning. Regulatory as in blocking by Justice or FTC on antitrust grounds.
My guess is that TEVA could navigate this. They would likely have to divest some products of either MYL or TEVA to get by.
I am also guessing that TEVA could get past the Netherlands stichting.
That is why I think MYL's best chance of avoiding TEVA is to buy PRGO.
Ultimately MYL management has to decide whether it is in the best interest of MYL equity holders to stay independent or merge with TEVA. Of course that decision is made more difficult by the self-interest of the management which will not want to give up the lucrative control of a major company.
Market Data 
Markets 
AI
